Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Eli LillyLLY · NYSE | 73 assets: 30 approved, 12 Ph 3, 16 Ph 2, 12 Ph 1, 3 other | eloralintidePhase 3 · ObesityReliable signal | Nov 2026Tirzepatide (Zepbound) · Phase 3 | $1.30T | $4.9BSep 2026 | Cash-flow positive | $15.4B |
Johnson & JohnsonJNJ · NYSE | 57 assets: 31 approved, 11 Ph 3, 4 Ph 2, 11 Ph 1 | SeltorexantPhase 3 · Major Depressive DisorderReliable signal | 8 Dec 2026Milvexian · Phase 3 | $656.5B | $17.2BSep 2026 | Cash-flow positive | $16.1B |
AbbVieABBV · NYSE | 78 assets: 22 approved, 9 Ph 3, 12 Ph 2, 25 Ph 1, 10 other | mesalamine (Asacol HD)US approval withdrawn · Ulcerative ColitisReliable signal | Nov 2026Budigalimab · Phase 2 | $505.6B | $10.8BSep 2026 | Cash-flow positive | $10.0B |
Merck & Co.MRK · NYSE | 54 assets: 19 approved, 19 Ph 3, 10 Ph 2, 3 Ph 1, 3 other | EnlicitidePhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Nov 2026Sacituzumab Tirumotecan · Phase 3 | $339.7B | $9.8BSep 2026 | Cash-flow positive | $30.8B |
NovartisNVS · NYSE | 89 assets: 32 approved, 13 Ph 3, 24 Ph 2, 12 Ph 1, 8 other | indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal | 27 Nov 2026Inclisiran · Approved | $294.9B | $11.5BDec 2025 | Cash-flow positive | $11.2B |
AstraZenecaAZN · Nasdaq | 114 assets: 36 approved, 26 Ph 3, 28 Ph 2, 20 Ph 1, 4 other | elecoglipronPhase 3 · ObesityReliable signal | 24 Nov 2026AZD0754 · Phase 1/2 | $277.3B | $7.6BMar 2026 | — | $14.6B |
AmgenAMGN · Nasdaq | 29 assets: 18 approved, 6 Ph 3, 2 Ph 2, 3 Ph 1 | Denosumab (Xgeva)Phase 3 · Multiple MyelomaReliable signal | 14 Dec 2026Abp 234 · Phase 3 | $240.1B | $13.2BSep 2026 | Cash-flow positive | $7.8B |
Gilead SciencesGILD · Nasdaq | 27 assets: 13 approved, 7 Ph 3, 5 Ph 2, 2 Ph 1 | filgotinibPhase 3 · Rheumatoid ArthritisReliable signal | Dec 2026Sacituzumab Govitecan · Phase 3 | $209.6B | $6.4BSep 2026 | Cash-flow positive | $6.3B |
AbbottABT · NYSE | 1 asset: 1 Ph 3 | SerplulimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Dec 2026Serplulimab · Phase 1 | $181.0B | $4.3BSep 2026 | Cash-flow positive | $3.3B |
Novo NordiskNVO · NYSE | 32 assets: 13 approved, 8 Ph 3, 5 Ph 2, 4 Ph 1, 2 other | repaglinideUS approval withdrawn · Type 2 DiabetesPartial signal | Dec 2026UBT251 · Phase 1 | $174.4B | $4.2BDec 2025 | Cash-flow positive | $7.9B |
PfizerPFE · NYSE | 95 assets: 43 approved, 19 Ph 3, 9 Ph 2, 13 Ph 1, 11 other | ecnoglutidePhase 3 · ObesityReliable signal | 29 Nov 2026Rimegepant (Nurtec ODT) · Phase 3 | $159.9B | $11.0BSep 2026 | Cash-flow positive | $11.5B |
Vertex PharmaceuticalsVRTX · Nasdaq | 15 assets: 7 approved, 3 Ph 3, 3 Ph 2, 1 Ph 1, 1 other | PovetaciceptPhase 3 · IgA Nephropathy | 15 Dec 2026VX-407 · Phase 1 | $136.0B | $6.3BSep 2026 | Cash-flow positive | $4.2B |
Bristol-Myers SquibbBMY · NYSE | 61 assets: 23 approved, 9 Ph 3, 18 Ph 2, 9 Ph 1, 2 other | MezigdomidePhase 3 · Multiple MyelomaPartial signal | Nov 2026Izalontamab brengitecan · Phase 3 | $121.9B | $12.6BSep 2026 | Cash-flow positive | $10.6B |
SanofiSNY · Nasdaq | 63 assets: 23 approved, 8 Ph 3, 12 Ph 2, 5 Ph 1, 15 other | GemigliptinPhase 3 · Type 2 DiabetesReliable signal | 25 Nov 2026rilzabrutinib · Phase 3 | $113.5B | $6.3BMar 2026 | — | $9.0B |
GlaxoSmithKlineGSK · NYSE | 73 assets: 26 approved, 8 Ph 3, 10 Ph 2, 10 Ph 1, 19 other | VilanterolPhase 3 · AsthmaPartial signal | 23 Nov 2026Dostarlimab · Phase 2 | $104.8B | $4.6BDec 2025 | Cash-flow positive | $9.9B |
Regeneron PharmaceuticalsREGN · Nasdaq | 51 assets: 8 approved, 10 Ph 3, 23 Ph 2, 9 Ph 1, 1 other | Freneslerbart/mevonlerbartPhase 3 · Allergic ConjunctivitisReliable signal | 4 Dec 2026ALN-ANG3 · Phase 1 | $97.4B | $9.3BSep 2026 | Cash-flow positive | $6.6B |
ModernaMRNA · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | Intismeran AutogenePhase 3 · Non-Small Cell Lung Cancer | 11 Dec 2026elasomeran · Approved | $79.6B | $5.2BSep 2026 | ~11.6 qtrs | $2.7B |
Takeda Pharmaceutical CompanyTAK · NYSE | 42 assets: 20 approved, 12 Ph 3, 6 Ph 2, 2 Ph 1, 2 other | zasocitinibPhase 3 · Psoriatic ArthritisReliable signal | Nov 2026Mirvetuximab soravtansine · Phase 2 | $67.7B | — | Profitable | $4.1B |
Teva Pharmaceutical IndustriesTEVA · NYSE | 13 assets: 10 approved, 2 Ph 3, 1 Ph 1 | Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal | 15 Jan 2027Emrusolmin · Phase 1 | $49.8B | $4.1BSep 2026 | Cash-flow positive | $1.8B |
BeOne MedicinesONC · Nasdaq | 10 assets: 6 approved, 2 Ph 3, 2 Ph 1 | BGB-43395Phase 3 · HR+/HER2- Metastatic Breast Cancer | Nov 2026Sonrotoclax · Phase 2 | $44.9B | $5.9BSep 2026 | Cash-flow positive | $2.4B |
BiogenBIIB · Nasdaq | 20 assets: 11 approved, 4 Ph 3, 3 Ph 2, 2 other | LitifilimabPhase 3 · Systemic Lupus ErythematosusReliable signal | 1 Dec 2026Felzartamab · Phase 3 | $37.2B | $1.3BSep 2026 | Cash-flow positive | $2.2B |
Revolution MedicinesRVMD · Nasdaq | 5 assets: 1 approved, 1 Ph 3, 1 Ph 2, 2 Ph 1 | ZoldonrasibPhase 3 · Non-Small Cell Lung Cancer | 31 Dec 2026Zoldonrasib · Phase 1 | $34.6B | $3.7BSep 2026 | ~10.2 qtrs | $1.5B |
GenmabGMAB · Nasdaq | 8 assets: 4 approved, 1 Ph 3, 2 Ph 2, 1 Ph 1 | Rinatabart sesutecan (Rina-S)Phase 3 · Ovarian Cancer | 31 Dec 2026Zenocutuzumab · Phase 2 | $31.8B | — | Cash-flow positive | $1.4B |
Insmed IncorporatedINSM · Nasdaq | 1 asset: 1 Ph 2 | OpSCFPhase 2 · Atopic DermatitisPartial signal | None on record | $26.3B | $1.1BSep 2026 | ~7.7 qtrs | $944M |
United TherapeuticsUTHR · Nasdaq | 7 assets: 6 approved, 1 Ph 3 | RalinepagPhase 3 · Pulmonary Arterial HypertensionReliable signal | Dec 2026Ralinepag · Phase 3 | $24.6B | $2.1BSep 2026 | Cash-flow positive | $703M |
IncyteINCY · Nasdaq | 13 assets: 9 approved, 4 Ph 3 | INCA033989Phase 3 · Essential Thrombocythemia | 9 Dec 2026Ruxolitinib (Opzelura) · Phase 1 | $24.0B | $3.9BSep 2026 | Cash-flow positive | $3.4B |
ViatrisVTRS · Nasdaq | 13 assets: 13 approved | Approved assets only | Jan 2027Sotagliflozin (Inpefa) · Phase 3 | $23.3B | $1.8BSep 2026 | Cash-flow positive | ~$979M |
BioNTechBNTX · Nasdaq | 9 assets: 4 Ph 3, 3 Ph 2, 2 Ph 1 | Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Nov 2026Beruzatatug pelitecan · Phase 2 | $21.1B | $9.0BDec 2025 | Cash-flow positive | $2.4B |
Alnylam PharmaceuticalsALNY · Nasdaq | 15 assets: 6 approved, 4 Ph 3, 3 Ph 2, 2 Ph 1 | ZilebesiranPhase 3 · HypertensionReliable signal | 27 Nov 2026Inclisiran · Approved | $19.8B | $3.6BSep 2026 | Cash-flow positive | $1.5B |
ExelixisEXEL · Nasdaq | 5 assets: 2 approved, 1 Ph 3, 2 Ph 1 | ZanzalintinibPhase 3 · Colorectal Cancer | 23 Nov 2026XB010 · Phase 1 | $16.7B | $892MOct 2026 | Cash-flow positive | ~$821M |
Neurocrine BiosciencesNBIX · Nasdaq | 6 assets: 3 approved, 2 Ph 3, 1 Ph 2 | DireclidinePhase 3 · SchizophreniaPartial signal | Jul 2027Osavampator · Phase 3 | $16.5B | $744MSep 2026 | Cash-flow positive | $1.2B |
Jazz PharmaceuticalsJAZZ · Nasdaq | 8 assets: 7 approved, 1 Ph 3 | Cannabidiol (JZP926)Phase 2/3 · Epilepsy | 31 Dec 2026Zanidatamab · Phase 2 | $15.5B | $2.9BSep 2026 | Cash-flow positive | $829M |
BridgeBio PharmaBBIO · Nasdaq | 1 asset: 1 approved | Approved assets only | 17 Sep 2027Acoramidis · Approved | $15.2B | $1.5BSep 2026 | ~16.7 qtrs | $536M |
Dr. Reddy's LaboratoriesRDY · NYSE | 4 assets: 2 approved, 2 Ph 3 | PyrotinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Pyrotinib · Phase 1/2 | $12.5B | $172MMar 2025 | Cash-flow positive | $323M |
Kymera TherapeuticsKYMR · Nasdaq | 1 asset: 1 Ph 2 | KT-621Phase 2 · Atopic DermatitisWeak signal | Apr 2027KT-621 · Phase 1 | $12.3B | $971MSep 2026 | ~13.5 qtrs | $430M |
BioMarin PharmaceuticalBMRN · Nasdaq | 10 assets: 8 approved, 1 Ph 3, 1 Ph 2 | BMN 333Phase 2/3 · Achondroplasia | 31 Dec 2026Migalastat · Phase 3 | $11.9B | $736MSep 2026 | Cash-flow positive | $988M |
Spyre TherapeuticsSYRE · Nasdaq | 4 assets: 4 Ph 2 | SPY003Phase 2 · Ulcerative ColitisPartial signal | Jun 2027SPY001 · Phase 2 | $9.6B | $1.1BSep 2026 | ~24.1 qtrswith a later raise | $260M |
Madrigal PharmaceuticalsMDGL · Nasdaq | 4 assets: 1 approved, 1 Ph 2, 1 Ph 1, 1 other | ErvogastatPhase 2 · MASH / NASHPartial signal | Dec 2026Resmetirom · Phase 3 | $9.2B | $962MSep 2026 | ~24.5 qtrs | $388M |
Praxis Precision Medicines, Inc.PRAX · Nasdaq | 4 assets: 4 Ph 3 | ElsunersenPhase 3 · EpilepsyPartial signal | Dec 2026Relutrigine · Phase 3 | $8.5B | $745MSep 2026 | ~9.3 qtrs | $289M |
Protagonist TherapeuticsPTGX · Nasdaq | 2 assets: 2 approved | Approved assets only | 10 Feb 2027icotrokinra · Phase 3 | $8.3B | $800MSep 2026 | Cash-flow positive | $176M |
Rhythm PharmaceuticalsRYTM · Nasdaq | 3 assets: 1 approved, 2 Ph 2 | bivamelagonPhase 2 · Hypothalamic ObesityPartial signal | 13 Mar 2027setmelanotide · Phase 3 | $8.3B | $321MSep 2026 | ~15.7 qtrs | $180M |
Corcept TherapeuticsCORT · Nasdaq | 4 assets: 2 approved, 2 Ph 2 | miricorilantPhase 2 · MASH / NASHPartial signal | Dec 2026Relacorilant (Lifyorli) · Phase 2 | $7.4B | $371MSep 2026 | Cash-flow positive | $242M |
AbivaxABVX · Nasdaq | 1 asset: 1 Ph 3 | obefazimodPhase 3 · Ulcerative ColitisReliable signal | Dec 2026obefazimod · Phase 2 | $7.3B | $460MJun 2026 | ~13.8 qtrswith a later raise | $216M |
ImmunityBioIBRX · Nasdaq | 2 assets: 1 approved, 1 Ph 1 | HankPhase 1 · Non-Small Cell Lung Cancer | Nov 2026Nogapendekin alfa inbakicept (Anktiva) · Phase 2 | $7.1B | $334MSep 2026 | ~4.7 qtrs | $190M |
Axsome TherapeuticsAXSM · Nasdaq | 6 assets: 3 approved, 2 Ph 3, 1 Ph 2 | ReboxetinePhase 3 · NarcolepsyPartial signal | Dec 2026Solriamfetol · Phase 3 | $7.0B | $314MSep 2026 | ~15.4 qtrs | $198M |
Immunovant, Inc.IMVT · Nasdaq | 1 asset: 1 Ph 3 | ImeroprubartPhase 3 · Myasthenia Gravis | May 2027Imeroprubart · Phase 2 | $6.9B | $722MSep 2026 | ~7.2 qtrs | ~$441M |
Oruka TherapeuticsORKA · Nasdaq | 2 assets: 2 Ph 2 | AvrukibartPhase 2 · PsoriasisPartial signal | Oct 2027ORKA-002 · Phase 2 | $6.5B | $920MSep 2026 | ~29.8 qtrs | $154M |
Kodiak Sciences Inc.KOD · Nasdaq | 3 assets: 3 Ph 3 | Tarcocimab tedromerPhase 3 · Age-Related Macular DegenerationReliable signal | Feb 2027Tabirafusp alfa · Phase 3 | $6.4B | $89MSep 2026 | ~2.1 qtrs | $208M |
CytokineticsCYTK · Nasdaq | 4 assets: 1 approved, 1 Ph 3, 1 Ph 2, 1 other | Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal | Sep 2027Omecamtiv mecarbil · Phase 3 | $6.4B | $1.1BSep 2026 | ~7.9 qtrs | $397M |
Arrowhead PharmaceuticalsARWR · Nasdaq | 16 assets: 1 approved, 3 Ph 3, 10 Ph 2, 2 Ph 1 | OlpasiranPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | 31 Dec 2026SRP-1003 · Phase 1/2 | $6.1B | $1.2BSep 2026 | ~17.5 qtrs | $739M |
Mirum Pharmaceuticals, Inc.MIRM · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | volixibatPhase 2 · Primary Sclerosing Cholangitis | Jan 2027volixibat · Phase 2 | $6.0B | $374MSep 2026 | ~5.5 qtrs | $347M |
Legend Biotech CorporationLEGN · Nasdaq | 2 assets: 1 approved, 1 other | LCAR-F33SMultiple Myeloma | 26 Feb 2027Ciltacabtagene autoleucel · Phase 2 | $6.0B | $902MDec 2025 | 10+ yearswith a later raise | $415M |
Ligand PharmaceuticalsLGND · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | VK2809Phase 2 · MASH / NASHPartial signal | None on record | $6.0B | $495MSep 2026 | Cash-flow positive | $23M |
Scholar RockSRRK · Nasdaq | 1 asset: 1 approved | Approved assets only | Jun 2028apitegromab · Phase 2 | $5.9B | $417MSep 2026 | ~5.4 qtrs | $211M |
Gossamer BioGOSS · Nasdaq | 1 asset: 1 Ph 3 | SeralutinibPhase 3 · Pulmonary Arterial HypertensionPartial signal | Dec 2026Seralutinib · Phase 3 | $5.6B | $51MSep 2026 | ~1.3 qtrs | $137M |
Liquidia CorporationLQDA · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | Treprostinil (L606)Phase 3 · Pulmonary Arterial Hypertension | Feb 2027Treprostinil (Yutrepia, Liquidia) · Phase 2 | $5.1B | $396MSep 2026 | Cash-flow positive | $72M |
PTC TherapeuticsPTCT · Nasdaq | 5 assets: 2 approved, 2 Ph 3, 1 Ph 2 | VolanesorsenPhase 3 · Familial Chylomicronemia SyndromeReliable signal | 31 Dec 2027Vatiquinone (PTC743) · Phase 3 | $5.0B | $2.1BSep 2026 | Cash-flow positive | $439M |
Cogent Biosciences, Inc.COGT · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 1 | bezuclastinibPhase 3 · Gastrointestinal Stromal Tumor | May 2028CGT4255 · Phase 1 | $4.8B | $792MSep 2026 | ~9.8 qtrs | $297M |
ErascaERAS · Nasdaq | 1 asset: 1 Ph 2 | ERAS-0015Phase 2 · Non-Small Cell Lung Cancer | 1 May 2028ERAS-0015 · Phase 1 | $4.8B | $644MSep 2026 | ~23.6 qtrs | $134M |
Travere Therapeutics, Inc.TVTX · Nasdaq | 1 asset: 1 approved | Approved assets only | Mar 2027sparsentan · Approved | $4.8B | $303MSep 2026 | Cash-flow positive | $246M |
Dianthus TherapeuticsDNTH · Nasdaq | 1 asset: 1 Ph 1 | LBL-047Phase 1 · Systemic Lupus Erythematosus | 16 Dec 2027LBL-047 · Phase 1 | $4.7B | $838MSep 2026 | ~19.1 qtrs | $189M |
Ionis PharmaceuticalsIONS · Nasdaq | 20 assets: 6 approved, 6 Ph 3, 6 Ph 2, 1 Ph 1, 1 other | InotersenUS approval withdrawn · Transthyretin Amyloidosis with PolyneuropathyReliable signal | Dec 2026Donidalorsen · Phase 3 | $4.6B | $1.9BSep 2026 | ~13.8 qtrs | $916M |
CRISPR TherapeuticsCRSP · Nasdaq | 4 assets: 1 approved, 2 Ph 2, 1 Ph 1 | SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease | Jun 2027CTX310 · Phase 1 | $3.9B | $2.3BSep 2026 | ~24.3 qtrs | $291M |
Tango TherapeuticsTNGX · Nasdaq | 2 assets: 2 Ph 2 | TNG456Phase 1/2 · Non-Small Cell Lung Cancer | 31 Mar 2027TNG456 · Phase 1/2 | $3.7B | $978MSep 2026 | ~26.1 qtrs | $152M |
Structure TherapeuticsGPCR · Nasdaq | 1 asset: 1 Ph 3 | aleniglipronPhase 3 · ObesityPartial signal | Aug 2027aleniglipron · Phase 1 | $3.7B | $1.2BSep 2026 | ~18.3 qtrs | $370M |
Xenon PharmaceuticalsXENE · Nasdaq | 1 asset: 1 Ph 3 | AzetukalnerPhase 3 · Major Depressive DisorderReliable signal | Jan 2027Azetukalner · Phase 3 | $3.6B | $951MSep 2026 | ~10.7 qtrs | $371M |
Relay Therapeutics, Inc.RLAY · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | ZovegalisibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Apr 2027Zovegalisib · Phase 1 | $3.6B | $125MSep 2026 | ~2.3 qtrs | $280M |
| 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | Galinpepimut-SPhase 3 · Acute Myeloid LeukemiaWeak signal | 30 Dec 2026Tambiciclib · Phase 1/2 | $3.6B | $135MSep 2026 | ~19.8 qtrs | $23M | |
Arcutis BiotherapeuticsARQT · Nasdaq | 3 assets: 2 approved, 1 Ph 1 | ARQ-234Phase 1 · Atopic Dermatitis | Apr 2028ARQ-234 · Phase 1 | $3.5B | $260MSep 2026 | Cash-flow positive | $81M |
Denali TherapeuticsDNLI · Nasdaq | 4 assets: 1 approved, 1 Ph 3, 1 Ph 2, 1 Ph 1 | BIIB122 / DNL151 (LRRK2 inhibitor)Phase 3 · Parkinson's DiseasePartial signal | Feb 2027DNL628 · Phase 1 | $3.5B | $519MSep 2026 | ~4.7 qtrs | $405M |
Iovance BiotherapeuticsIOVA · Nasdaq | 5 assets: 2 approved, 3 Ph 2 | LN-145Phase 2 · Non-Small Cell Lung CancerWeak signal | Sep 2027IOV-4001 · Phase 1/2 | $3.5B | $382MSep 2026 | ~8.1 qtrs | $240M |
Amylyx Pharmaceuticals, Inc.AMLX · Nasdaq | 1 asset: 1 Ph 3 | avexitidePhase 3 · Post-Bariatric HypoglycemiaPartial signal | None on record | $3.4B | $768MSep 2026 | ~23.7 qtrs | $101M |
Supernus PharmaceuticalsSUPN · Nasdaq | 10 assets: 7 approved, 3 Ph 2 | SPN-820Phase 2 · Major Depressive DisorderPartial signal | Dec 2026viloxazine · Phase 3 | $3.4B | $361MSep 2026 | Cash-flow positive | $122M |
Viking TherapeuticsVKTX · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | VK2735Phase 3 · ObesityReliable signal | May 2027VK2735 · Phase 1 | $3.3B | $960MSep 2026 | ~8.3 qtrs | $586M |
Bausch HealthBHC · NYSE | 15 assets: 13 approved, 1 Ph 3, 1 Ph 2 | Rifaximin SSDPhase 3 | 20 Apr 2027Rifaximin (Xifaxan) · Approved | $3.3B | $2.5BSep 2026 | Cash-flow positive | $638M |
Definium TherapeuticsDFTX · Nasdaq | 1 asset: 1 Ph 3 | Lysergide tartrate (LSD)Phase 3 · Major Depressive DisorderReliable signal | Sep 2027Lysergide tartrate (LSD) · Phase 3 | $3.2B | $1.0BSep 2026 | ~21.9 qtrs | $170M |
Acadia PharmaceuticalsACAD · Nasdaq | 4 assets: 2 approved, 1 Ph 3, 1 Ph 2 | RemlifanserinPhase 3 · Alzheimer's Disease | Aug 2027ACP-211 · Phase 2 | $3.1B | $976MSep 2026 | Cash-flow positive | $319M |
Vericel CorporationVCEL · Nasdaq | 1 asset: 1 approved | Approved assets only | Feb 2030autologous cultured chondrocytes on porcine collagen membrane · Phase 3 | $3.0B | $170MSep 2026 | Cash-flow positive | $30M |
Disc MedicineIRON · Nasdaq | 3 assets: 1 Ph 3, 2 Ph 2 | BitopertinPhase 3 · Erythropoietic ProtoporphyriaPartial signal | May 2027Selcodebart · Phase 1/2 | $3.0B | $683MSep 2026 | ~14.4 qtrs | $183M |
Silence TherapeuticsSLN · Nasdaq | 1 asset: 1 Ph 2 | ZerlasiranPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record | $2.8B | $248MSep 2026 | ~22.4 qtrs | $36M |
Celcuity Inc.CELC · Nasdaq | 1 asset: 1 approved | Approved assets only | Jan 2028Gedatolisib · Phase 1/2 | $2.7B | $643MSep 2026 | ~12.1 qtrs | $139M |
XencorXNCR · Nasdaq | 6 assets: 1 approved, 1 Ph 2, 4 Ph 1 | XmAb942Phase 1/2 · Ulcerative Colitis | Feb 2027XmAb819 · Phase 1 | $2.6B | $383MSep 2026 | ~8.9 qtrs | $286M |
IDEAYA BiosciencesIDYA · Nasdaq | 6 assets: 1 Ph 3, 2 Ph 2, 3 Ph 1 | DarovasertibPhase 3 · Uveal MelanomaPartial signal | 7 Jan 2027Tuvutromstat · Phase 1 | $2.6B | $840MSep 2026 | ~9.7 qtrs | $413M |
HUTCHMEDHCM · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | SavolitinibPhase 3 · Non-Small Cell Lung CancerPartial signal | 18 Jan 2027Savolitinib · Phase 2 | $2.4B | $1.4BDec 2025 | 10+ years | $148M |
NewAmsterdam PharmaNAMS · Nasdaq | 2 assets: 2 Ph 3 | ObicetrapibPhase 3 · Type 2 DiabetesPartial signal | Nov 2026Obicetrapib · Phase 3 | $2.3B | $628MSep 2026 | ~16.7 qtrs | $158M |
Arcus BiosciencesRCUS · Nasdaq | 4 assets: 2 Ph 3, 2 Ph 1 | CasdatifanPhase 3 · Clear Cell Renal Cell Carcinoma | May 2027Casdatifan · Phase 1 | $2.3B | $630MSep 2026 | ~15.9 qtrs | $473M |
Lakefront Biotherapeutics NVLKFT · Nasdaq | 1 asset: 1 Ph 3 | Gamgertamig (CM336)Phase 3 · Multiple Myeloma | Dec 2026Gamgertamig (CM336) · Phase 1/2 | $2.2B | $3.4BMar 2026 | — | $364M |
Beam Therapeutics Inc.BEAM · Nasdaq | 4 assets: 3 Ph 2, 1 other | BEAM-301Phase 1/2 · Glycogen Storage Disease Type Ia | 30 Dec 2027BEAM-301 · Phase 1/2 | $2.2B | $1.1BSep 2026 | ~10.8 qtrs | $409M |
Celldex TherapeuticsCLDX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | barzolvolimabPhase 3 · Chronic Spontaneous UrticariaPartial signal | Mar 2027CDX-622 · Phase 1 | $2.2B | $650MSep 2026 | ~10.8 qtrs | $283M |
Immunome, Inc.IMNM · | 3 assets: 1 Ph 3, 2 Ph 1 | VaregacestatPhase 2/3 · Desmoid TumorsPartial signal | May 2027Varegacestat · Phase 1 | $2.0B | $462MSep 2026 | ~8.1 qtrs | $227M |
Harmony BiosciencesHRMY · Nasdaq | 3 assets: 1 approved, 1 Ph 3, 1 other | Clemizole (EPX-100)Phase 3 · Epilepsy | 30 Dec 2026Clemizole (EPX-100) · Phase 1 | $1.9B | $771MSep 2026 | Cash-flow positive | $238M |
BiohavenBHVN · NYSE | 7 assets: 5 Ph 3, 1 Ph 2, 1 Ph 1 | TroriluzolePhase 3 · Spinocerebellar AtaxiaPartial signal | Dec 2026Opakalim · Phase 2/3 | $1.9B | $164MSep 2026 | ~1.4 qtrs | $428M |
Trevi Therapeutics, Inc.TRVI · Nasdaq | 1 asset: 1 Ph 3 | Nalbuphine ERPhase 3 · Chronic Cough in Idiopathic Pulmonary Fibrosis | 30 Nov 2026Nalbuphine ER · Phase 1 | $1.9B | $299MSep 2026 | ~19.5 qtrs | $50M |
First Tracks BiotherapeuticsTRAX · Nasdaq | 1 asset: 1 Ph 2 | RosnilimabPhase 2 · Rheumatoid Arthritis | None on record | $1.9B | $156MSep 2026 | ~5.7 qtrs | ~$117M |
Replimune, Inc.REPL · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | Sturlimogene erparepvecPhase 2/3 · Uveal Melanoma | 1 Dec 2027Sturlimogene erparepvec · Phase 2 | $1.9B | $310MSep 2026 | ~4.6 qtrs | ~$195M |
Vera Therapeutics, Inc.VERA · Nasdaq | 1 asset: 1 approved | Approved assets only | Nov 2027Atacicept · Phase 2 | $1.8B | $384MSep 2026 | ~4.1 qtrs | $247M |
Ultragenyx Pharmaceutical Inc.RARE · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | setrusumabPhase 3 · Osteogenesis ImperfectaPartial signal | Jan 2027setrusumab · Phase 3 | $1.8B | $266MSep 2026 | ~2.4 qtrs | $711M |
ZymeworksZYME · Nasdaq | 2 assets: 2 approved | Approved assets only | 31 Dec 2026Zanidatamab · Phase 2 | $1.8B | $100MSep 2026 | ~3.6 qtrs | $129M |
Zenas BioPharmaZBIO · Nasdaq | 1 asset: 1 Ph 3 | ObexelimabPhase 3 · IgG4-Related DiseasePartial signal | None on record | $1.8B | $585MSep 2026 | ~9.6 qtrs | $238M |
AGIOS PHARMACEUTICALS, INC.AGIO · Nasdaq | 2 assets: 2 approved | Approved assets only | Mar 2029Mitapivat · Phase 3 | $1.8B | $630MSep 2026 | ~7.6 qtrs | $343M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.